Chronotype Profiling in Patients with Non-Alcoholic Fatty Liver Disease

Chronotype Profiling in Patients with Non-Alcoholic Fatty Liver Disease - NAFLD-Chronotyping

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00033642

Enrollment

100

Registered

2024-02-15

Start date

2023-11-16

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Steatotic liver disease (SLD) [K76.0, K75.8] K76.0 K75.8

Interventions

Group 1: Two groups are examined: a control group and a patient group. The examinations are the same in both groups. The only difference is that liver tissue samples can be taken from the patients. Ho

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: NAFLD patients: 1. diagnosed non-alcoholic fatty liver disease (NAFLD). 2. declaration of consent to participate in the study and privacy policy. Liver-healthy controls: 1. exclusion of non-alcoholic fatty liver disease (NAFLD). 2. age / gender / body mass index matched to an already recruited patient. Age match included ±2 years. 3. declaration of consent to participate in the study and privacy policy.

Exclusion criteria

Exclusion criteria: Controls and NAFLD patients: 1. age under 18 years. 2. taking medication or other current therapies that may affect sleep. sleep may be affected. 3. presence of other chronic liver disease (viral hepatitis, autoimmune hepatitis, alcoholic liver disease, cholangitis, drug-associated liver damage, etc.). 4. presence of a tumor disease. 5. moderate to severe psychopathological disorders 6. eye diseases or other conditions that do not permit light dosimetry. 7. lack of prerequisites for the performance of actigraphy (e.g. physical illnesses that are associated with a significant restriction of physical activity) 8. lack of prerequisites for keeping the required diaries. 9. pregnancy or breastfeeding. 10. traveling across time zones during the outpatient study phase.

Design outcomes

Primary

Measure	Time frame
Establish comprehensive multiparametric circadian rhythms for patients with NAFLD and healthy controls.	—

Secondary

Measure	Time frame
Identification of differences between healthy controls and patients with NAFLD in terms of frequency and extent of disruption of circadian rhythms (chronodisruption).	—

Countries

Germany

Contacts

Public ContactJan-Peter Sowa

Universitätsklinikum Knappschaftskrankenhaus Bochum

jan.sowa@rub.de+49 234 299-80197

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026